Consensual recommendations for outpatient management and home care
and home treatment of patients with COVID-19
Dans la plupart des pays, les services de lutte contre la tuberculose (TB) sont décentralisés jusqu’aux dispensaires
les plus périphériques et souvent au sein même des villages et des quartiers. Par contre, les services
de lutte contre le VIH/Sida sont généralement beaucoup plus centralis...és parce que la diffusion des
soins, notamment de la thérapie antirétrovirale (TARV), n’a commencé qu’assez récemment. De ce fait,
les patients qui ont besoin d’un traitement à la fois contre la tuberculose et le VIH/Sida peuvent être obligés
de se rendre dans deux établissements distincts et ainsi d’avoir à parcourir de longues distances pour
accéder aux soins. L’absence de services intégrés TB/VIH peut provoquer des retards dans le diagnostic
et le traitement, et même se traduire par un mauvais suivi des traitements, voire par des interruptions. Par
ailleurs, les patients ont à supporter la charge financière des frais de déplacement et des autres coûts indirects,
tels que de longs temps d’attente et une perte de revenu
more
Eur Respir J 2014; 43: 24–35 | DOI: 10.1183/09031936.00113413
COVID-19 Management Guide -Version June 2021
Approaches pratiques pour des interventions collaboratives
AGOSTO – DICIEMBRE 2020
La evolución de la pandemia COVID-19 desde el mes de marzo que se reportó el primer caso ha impactado muy fuertemente al sistema de salud pública y privada del país debido principalmente al número de casos y personas fallecidas.
6a edición clínica. Nuevo: 4. Vacunas (26 de abril); Nuevo: 5. Pruebas y procedimientos de diagnóstico (7 de abril); Nuevo: 7. COVID-19 persistente (7 de abril)
Клинический протокол для Европейского региона ВОЗ
1 marco 2021. As orientações deste documento visam, principalmente, equipar o pessoal da saúde com ferramentas que lhes permitam aumentar a eficiência da comunicação com a população geral e aumentar, manter ou recuperar a confiança do público nas vacinas e nos programa de imunização na R...egião das Américas.
more
orientaciones provisionales, 8 de noviembre de 2020
Mass population movements have accounted for the emergence of Chagas disease (CD) outside endemic regions,
including the European Union/European Economic Area (EU/EEA). The parasite responsible for causing CD,
Trypanosoma cruzi (T. cruzi), can be transmitted through substances of human origin (SoH...O), such as blood
transfusions and organ transplantations [1], posing a risk to the recipients. This, together with congenital
transmission, is of increasing concern in non-endemic countries
more
How to address the global crisis in antibiotic research and development.
The report includes a comprehensive summary and critical evaluation of recent initiatives to overcome the barriers to achieve sustainable access to antibiotics. As antibiotic resistance will continue to develop as long as we ...depend on these medicines to treat bacterial infections, a continuous supply of new effective antibiotics is needed. The report identifies five key challenges that must be solved in order to achieve sustainable access for all, and charts out options for governmental action in response to each of them.
more
orientaciones provisionales, 23 de abril de 2020
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more